The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely expl...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Frontiers in immunology Ročník 8; s. 631
Hlavní autoři:	Veluchamy, John P., Kok, Nina, van der Vliet, Hans J., Verheul, Henk M. W., de Gruijl, Tanja D., Spanholtz, Jan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland Frontiers Media S.A 31.05.2017
Témata:	adoptive natural killer cell therapy allogeneic natural killer cells autologous natural killer cells hematopoietic stem cell transplantation Immunology natural killer cell biotech companies natural killer cell combinatorial studies adoptive natural killer cell therapy hematopoietic stem cell transplantation natural killer cell combinatorial studies allogeneic natural killer cells natural killer cell biotech companies autologous natural killer cells
ISSN:	1664-3224, 1664-3224
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Specialty section: This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology Edited by: Gianfranco Pittari, Hamad Medical Corporation, Qatar These authors have contributed equally to this work. Reviewed by: Evelyn Ullrich, Goethe University Frankfurt, Germany; Bjarne Kuno Møller, Aarhus University Hospital, Denmark
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2017.00631